Opioid litigation should serve the public interest, not trial lawyers’ bottom lines

Published



The Centers for Disease Control and Prevention last Thursday reported that prescriptions written for opioid painkillers dropped more than 13 percent between 2012 and 2015. On the same day, the maker of one such federally regulated medicine agreed to the Food and Drug Administration’s request to halt sales of its product. But even as Americans can be encouraged by responsible authorities’ increasing engagement and determination to address our nation’s complex problems with opioid abuse, we can all agree that those problems won’t be solved overnight.

We also should be able to agree that elected policymakers, the expert regulators they appoint, the medical and scientific communities, and law enforcement should be working cooperatively to advance the interests of public health and safety. Which is why the American Tort Reform Association is raising concerns about the reported involvement of largely self-interested personal injury lawyers in developing litigation, ostensibly led by state attorneys general, that targets drugmakers.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.